Trials / Completed
CompletedNCT02514694
LEO 32731 - A Phase I Study in Healthy Subjects
LEO 32731 - A Phase I, Single-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis. The aim (s) of this Study are to determine: * The safety and tolerability of the Study Drug and any side effects that might be associated with it * The Study will also measure how much of the Study Drug that gets into the blood and how long time it takes for the body to remove it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO32731 | |
| OTHER | Placebo |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-08-04
- Last updated
- 2017-05-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02514694. Inclusion in this directory is not an endorsement.